Achieving Superior Treatment Durability and Outcomes in Neovascular AMD and DME


Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

0:00 Introduction

0:52 Need for durable treatments in nAMD and DME

4:20 Mechanism of faricimab

7:10 Highlights from clinical trials for faricimab

10:28 Post hoc analyses of faricimab clinical trials

16:19 Factors affecting retreatment decision

19:20 Durability data for faricimab

23:22 Experience with faricimab

29:00 Choosing between faricimab and high-dose aflibercept

32:47 Final remarks

Related Videos
Jean-Francois Korobelnik, MD | Image Credit: American Society of Retina Specialists
© 2023 MJH Life Sciences

All rights reserved.